AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HEMAB THERAPEUTICS HOLDINGS
US
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG021LKFWY3
34.40▲ 5.16 (17.65%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
29.24
Day's Range
26.81 – 29.47
52-Week Range
23.00 – 36.61
Volume
1.5M
Avg Volume
234.1K
Share Statistics
Shares Outstanding
Employees
—
Exchange
US
Listed
—
Share count as of July 31, 2026

HEMAB THERAPEUTICS HOLDINGS (COAG) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about HEMAB THERAPEUTICS HOLDINGS (COAG)
What is HEMAB THERAPEUTICS HOLDINGS's Market Cap?
HEMAB THERAPEUTICS HOLDINGS's Market Cap is $1.6B, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · COAGAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense), net:
Interest income
Other (expense) income, net
Total other income, net
Loss before income tax expense
Income tax (expense) benefit
Net loss
Net loss per share, basic
Net loss per share, diluted